Cancer immunotherapy: tumour-immune system interaction, key immunotherapy technologies and mechanisms of action Tumours, the immune system and their interaction with immunotherapy Key immunotherapy technologies Mechanisms of action of leading cancer immunotherapies Interleukin-2 (IL-2) and interferon-alpha (IFN- ?
Clinical data summary for key cancer immunotherapies Key data for Yervoy (ipilimumab; Bristol-Myers Squibb) Melanoma Yervoy in lung cancer Key data for nivolumab (BMS-936558; BMS) Metastatic melanoma NSCLC Renal cell carcinoma Key data for MPDL3280A (Roche) Phase I Study of MPDL3280A (Roche) in patients with Locally Advanced or Metastatic Solid Tumours (NCT01375842) A Phase I study in metastatic urothelial bladder cancer Pembrolizumab (MK-3575, Merck & Co.
How cancer immunotherapies potentially fit into current treatment paradigms Advanced melanoma Current protocol Potential role of immunotherapy in the protocol for melanoma Checkpoint inhibitors in BRAF mutation tumours Protocol for other cancers Lung cancer
Key issues in the clinical development and design of cancer immunotherapies and their trials Clinical development endpoints specific to immunotherapy trials Immune response criteria Landmark Endpoints Indications: single or multiple tumour types?
Critical success factors for commercial uptake of cancer immunotherapies Education and marketing Educating the patient Educating the clinician Having a rich and diverse pipeline Cost and reimbursement Duration of treatment Cost as a function of efficacy and survival Market expansion Influence of the oncology community Analysis and comparison of key late-stage checkpoint inhibitors CTLA-4, PD-1 or PD-L1?
With a rapidly expanding clinical development pipeline, Argos is already in a strong position and I look forward to leading the Company in its mission to deliver on the promise of autologous immunotherapies.
eIuResearch in RNA-loaded dendritic cell immunotherapies for HIV treatment may provide the next important and effective treatment option for infectious disease,eIN stated Dr.
The award will cover substantially all of the costs associated with the development of the next-generation HIV immunotherapies, as well as portions of costs related to ArgoseIU current HIV candidate development.
The signing of the CRADA represents an important opportunity for OMRIX to leverage its expertise in the rapid development and deployment of antibody-based immunotherapies that address emerging viral threats," stated Robert Taub, President and Chief Executive Officer.